← ANALYST RATINGS · TIPRANKS

Damora Therapeutics (DMRA): analyst forecast and price target

$18.44 −1.60% close 16.10.26 · market cap $1.1B · Healthcare · Biotechnology IWM 0.03%
Price targets and ratings of

Analyst consensus

Strong Buy

7 Buy0 Hold0 Sell

Ratings of 7 analysts in the last 3 months

12-month forecast

$46.67+153.1% upside

Based on 7 price targets given in the last 3 months, the average target is $46.67, the highest $60.00, the lowest $40.00. The average is +153.1% from the last price of $18.44.

$20.00$40.00$60.00Jan 26AprJulOctJan 27AprJulOctHigh$60.00Average$46.67Low$40.00
Highest target $60.00 Average target $46.67 Lowest target $40.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% Wedbush $40.00 Buy +116.9% Reiterated 29.09.26on TipRanks 10:15 −0.2%next day +3.2% · 5 days −7.3%
Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% Guggenheim $40.00 → $60.00+50.0% Buy +225.4% Reiterated 24.09.26on TipRanks Sep 25 08:31 −0.7%next day +1.4% · 5 days +0.2%
Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% LifeSci Capital $45.00 Buy +144.0% Reiterated 18.09.26on TipRanks 16:35 −0.4%next day −1.9% · 5 days −8.2%
Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% Jefferies $50.00 Buy +171.1% Reiterated 11.08.26on TipRanks 10:55 +3.1%next day +1.9% · 5 days +5.1%
Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% H.C. Wainwright $45.00 Buy +144.0% Reiterated 11.08.26on TipRanks 06:25 +3.1%next day +1.9% · 5 days +5.1%
Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% RBC Capital $40.00 Buy +116.9% Reiterated 10.08.26on TipRanks Aug 11 06:45 −1.2%next day +3.1% · 5 days +5.3%
Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% TD Cowen — Buy — Reiterated 10.08.26on TipRanks Aug 11 02:45 −1.2%next day +3.1% · 5 days +5.3%
Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% Leerink Partners $55.00 → $51.00−7.3% Buy +176.6% Reiterated 15.05.26on TipRanks 11:20 +4.2%next day +1.3% · 5 days +2.0%
Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% Evercore ISI $46.00 Buy +149.5% Initiated 25.03.26on TipRanks 09:25 +4.2%next day +4.1% · 5 days +0.4%
Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% UBS $45.00 Buy +144.0% Initiated 17.02.26on TipRanks Mar 11 17:10 +2.6%next day +1.5% · 5 days +5.5%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Damora Therapeutics

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Bradley Canino★★★★★★★★★★Guggenheim · #1614
Hits 46%114 of 246 Average return +10.8%
1 year Bradley Canino★★★★★★★★★★Guggenheim · #1614
Hits 46%114 of 246 Average return +10.8%
2 years Bradley Canino★★★★★★★★★★Guggenheim · #1614
Hits 46%114 of 246 Average return +10.8%

Most profitable

3 months Bradley Canino★★★★★★★★★★Guggenheim · #1614
Hits 46%114 of 246 Average return +10.8%
1 year Bradley Canino★★★★★★★★★★Guggenheim · #1614
Hits 46%114 of 246 Average return +10.8%
2 years Bradley Canino★★★★★★★★★★Guggenheim · #1614
Hits 46%114 of 246 Average return +10.8%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $46.67 at a price of $21.28 (+119.3%); now: $46.67 at $18.44 (+153.1%).

$20.00$30.00$40.00Sep 15Oct 1Oct 15Top analysts$46.67Average target$46.67Price$18.44

PriceAverage targetTop analysts’ target

Recommendation trend

05101520Oct 251Nov11Dec21Jan 2624Feb43Mar53Apr81May123Jun115Jul911Aug69Sep57Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy81211965
Buy1351197
Hold000000
Sell000000

Earnings and sales forecast

Next report: 30.10.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.48 (from $-0.60 to $-0.37). Last quarter: $-0.39.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Damora Therapeutics
  • CEO: Jennifer A. Jarrett
  • Employees: 7
  • Building 23, Waltham, MA, 02453, US
  • www.damoratx.com

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Data from the stock’s TipRanks forecast page, read 118 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗